It is now established that proteolytic cleavage of key cellular substrates is a fundamental biochemical event underlying the apoptotic process (Casciola-Rosen et al, 1996) . One of the most intensively studied of these proteases, caspase 3 (previously termed CPP32/Yama/apopain), normally resides in the cytosolic fraction of cells as an inactive precursor and is proteolytically activated in cells undergoing apoptosis (Schlegel et al, 1996) . Increasing numbers of caspase 3 substrates have been identified and include poly(ADP-ribose) polymerase (PARP) (Nicholson et al, 1995) , sterol regulatory element binding proteins , the U1-associated 70-kDa protein (Casciola-Rosen et al, 1996) , DNA-dependent protein kinase (Casciola-Rosen et al, 1996) and DNA fragmentation factor (DFF) . Recent studies have demonstrated that caspase 3 activation and DNA fragmentation are directly linked through the caspase-3-mediated cleavage of DNA fragmentation factor (DFF) (also known as inhibitor of caspase-activated deoxyribonuclease, ICAD), a cytosolic factor which binds to and inhibits the activity of an endonuclease (caspase-activated nuclease, CPAN or caspase-activated deoxyribonuclease, CAD) directly responsible for DNA fragmentation during apoptosis Enari et al, 1998; Halenbeck et al, 1998 . This endonuclease, CAD/CPAN, is only activated during apoptosis and is, therefore, believed to be responsible for DNA fragmentation (Halenbeck et al, 1998; Sakahira et al, 1998) . We have shown that caspase-3-dependent cleavage of DFF occurs in PDTtreated HL-60 (Granville et al, 1998b) and HeLa cells (Carthy et al, 1998) .
Caspase 6 (Mch2) is also mobilized in response to certain apoptotic stimuli (Fernandes-Alnemri et al, 1995; Orth et al, 1996; Srinivasula et al, 1996) . Caspase 6 is believed to be responsible
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for nuclear lamin cleavage which may contribute to the nuclear degradation observed during apoptosis (Orth et al, 1996; Srinivasula et al, 1996; Takahashi et al, 1996) .
One of the most studied cell survival genes is Bcl-2 (Gajewski and Thompson, 1996; Reed, 1997) . Bcl-2 was discovered as an overexpressed protein in human B-cell lymphomas arising as a result of a t(14;18) chromosomal translocation (Pegoraro et al, 1984; Tsujimoto et al, 1985) . The overexpression of Bcl-2 has been shown to protect different cell types against apoptosis induced by such diverse stimuli as viral infection, hypoxia, ionizing radiation or chemotherapeutic agents (Shimizu et al, 1995; Gajewski and Thompson, 1996; Ibrado et al, 1996 Ibrado et al, , 1997 Reed, 1996) . Bcl-2 overexpression in Chinese hamster ovary cells provided partial protection against the loss of clonogenicity produced by PDT using phthalocyanine Pc4 (He et al, 1996) , supporting a role for Bcl-2 in the regulation of PDT-induced apoptosis. Several members of the Bcl-2 family have been identified in mammals: Bcl-2, Bcl-X L , A1/Bfl-1, Bcl-w, Nr13 and Mcl-1 serve to inhibit apoptosis, whereas Bax, Bik, Bak, Bad and Bcl-X S promote apoptosis (Reed, 1996; Nagata, 1997) . Members of the Bcl-2 family have been shown to homo-or heterodimerize with one another to either antagonize or enhance the function of the other (Yang et al, 1995; Reed, 1996) . In vivo and in vitro studies showed that Bcl-2 provides protection against apoptosis in the absence of protein translation, suggesting that it does not exert its protective effect through gene regulation (Rowan and Fisher, 1997) . Bcl-2 is an integral membrane protein that is situated primarily on the outer membranes of mitochondria, endoplasmic reticulum and nuclei (Nagata, 1997; Yang et al, 1997) . In some systems, Bcl-2 regulates intracellular Ca 2+ levels and prevents the loss of mitochondrial membrane potential produced by proapoptotic stimuli (Rowan and Fisher, 1997) . Recent evidence suggests that Bcl-2 may act as an ion channel and regulate the release of cytochrome c from the mitochondria, an event that may be necessary for caspase 3 activation (Kluck et al, 1997; Yang et al, 1997) .
We have previously demonstrated that caspase 3, but not caspase 1, is activated leading to PARP and DNA-PK cleavage in HL-60 cells treated with cytotoxic levels of BPD-MA and light (Granville et al, 1997 ). The present report shows that although Bcl-2 overexpression effectively blocked caspase 3 and caspase 6 activation as well as hypodiploid DNA formation produced by PDT, Bcl-2 had little or no effect on cell death induced by the photoactivation of BPD-MA at high drug doses but did offer a degree of protection against killing at lower levels of the photosensitizer as determined by 3-day culture studies.
MATERIALS AND METHODS

Reagents and cell culture
Liposomally formulated BPD-MA was from QLT PhotoTherapeutics (Vancouver, BC, Canada). All antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). All other drugs and chemicals, unless specified, were obtained from Sigma Chemical (St. Louis, MO, USA). The transfected human promyelocytic leukaemia HL-60/neo and HL-60/Bcl-2 cell lines were generously provided by Dr Kapil Bhalla (Emory University School of Medicine, Atlanta, GA, USA). Detailed methods used to generate these clones have been previously described (Ibrado et al, 1996) . The HL-60/Bcl-2 cells used in this study contain a fivefold higher level of Bcl-2 than the HL-60/neo control cells, whereas Bcl-X L and Bax levels are comparable for both transfectants (Ibrado et al, 1996) . Cells were maintained in RPMI-1640 medium supplemented with 10% heatinactivated fetal bovine serum (FBS), 4 mM L-glutamine, 1 mM sodium pyruvate, 1 mM Hepes, penicillin (100 U ml -1 ) and streptomycin (100 µg ml -1 ) (Gibco, Burlington, Ontario, Canada) and G418 (1 mg ml -1 ) (Geneticin; Life Technologies, Grand Island, NY, USA).
PDT and inhibitor treatment of cells
For photodynamic studies, cells were incubated for a total of 60 min at 37°C with BPD-MA (0-200 ng ml -1 ) in RPMI containing 10% FBS. After incubation with BPD-MA, cells were exposed to fluorescent red light (620-700 nm) delivered at 5.6 mW cm -2 to give a total dose of 2 J cm -2 . For caspase 3 inhibition studies, Z-DEVD-fmk (Enzyme Systems Products, Dublin, CA, USA) was added to the cells to give final concentrations of 10, 20 or 25 µM for the final 30 min before photoactivation.
Analysis of DNA status
The propidium iodide (PI) fluorescence analysis procedure was used to detect changes in the status of cellular DNA (Darzynkieicz et al, 1992; Telford et al, 1994) . At 3 h, after PDT, 1 × 10 6 cells were washed twice with ice-cold PBS then permeabilized and fixed in 80% ethanol at 4°C for 1 h. Cells were washed twice in ice-cold PBS and treated with RNAase (5 U ml -1 , DNAase-free) and stained with PI (50 µg ml -1 ) in PBS. Samples were analysed by flow cytometry. The percentage of cells containing hypodiploid levels of DNA was calculated from single parameter flow cytometry for PI fluorescence (Telford et al, 1994) using an Epics XL flow cytometer (Coulter Electronics, Hialeah, FA, USA).
Preparation of cellular protein extracts
To prepare cell lysates, cells were initially washed twice with icecold PBS. Cell pellets were treated with 1 ml of lysis buffer [1% Nonidet P-40 detergent (NP-40), 20 mM Tris, pH 8, 137 mM sodium chloride, 10% glycerol] supplemented with 1 mM phenylmethylsulphonyl fluoride (PMSF), aprotinin (0.15 U ml -1 ) and 1 mM sodium orthovanadate for 20 min on ice. Lysates were centrifuged for 10 min at 15 800 g at 4°C. Protein concentrations of cell extracts were determined with the Pierce BCA protein assay (Pierce, Rockford, IL, USA).
Protease assay
To evaluate caspase 3 activity, cell lysates were prepared 1 h after their respective treatment. Assays were performed in 96-well microtitre plates by incubating 25 µl (10 µg protein) of cell lysate in 125 µl of reaction buffer (1% NP-40, 20 mM tris-HCl, pH 7.5, 137 mM sodium chloride, 10% glycerol) containing the caspase-3 substrate [Acetyl-Asp-Glu-Val-Asp-amino-4-methylcoumarin (Ac-DEVD-AMC)] (Calbiochem, Cambridge, MA, USA) at 100 µM. Lysates were incubated at 37°C for 16 h and fluorescence levels were determined using a CytoFluor 2350 (PerSeptive Biosystems, Burlington, ON, USA) set at excitation and emission wavelengths of 380 nm and 460 nm respectively.
Immunoblot analysis
Detergent-soluble proteins (30 µg) were separated by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) in 12% gels, under reducing conditions (Laemmli, 1970) . Proteins were transferred to nitrocellulose membranes at 100 V for 1 h. Membranes were blocked for 30 min at room temperature with 5% skimmed milk powder in PBS-0.05% Tween 20 (PBS-T). Membranes were incubated for 45 min using the following polyclonal antibodies: goat-anti-PARP, goat-anti-CPP32, goat-anti-Mch2 or rabbit-anti-Bcl-2 at 1 µg ml -1 . Membranes were then probed with anti-goat IgG-HRP or anti-rabbit IgG-HRP (1:5000) in PBS-T with 1% skimmed milk powder for 30 min at room temperature. Membranes were rinsed twice in PBS-T, followed by three 15-min washes with PBS-T. Proteins were detected using the enhanced chemiluminescence detection system (Amersham, Arlington Heights, IL, USA) and bands visualized by autoradiography.
Assessment of cell viability using MTT
To assess cell viability, 5 × 10 4 cells were loaded into eight replicate wells (0.2 ml per well) of 96-well microtitre plates. After 3, 24, 48 or 72 h, 10 µl of a MTT solution (5 mg ml -1 ) was added to each well (Mosmann, 1983) . Cells were incubated for a further 1 h at 37°C. The reaction was stopped by the addition of 150 ml of acidified isopropanol. The degree of colour development was analysed with an automated densitometer microtitre plate reader (Dynatech, Hamilton, VA, USA) using a 590-nm filter.
RESULTS
Caspase 6 activation occurs downstream of caspase 3
To assess the involvement of caspases in PDT-induced apoptosis, wild-type HL-60 cells were treated with different amounts of the caspase 3 inhibitor Z-DEVD-fmk before BPD-MA photoactivation. The presence of Z-DEVD-fmk did not affect PDT-induced caspase-3 cleavage and the appearance of the 12-kDa cleavage product at the concentrations tested (Figure 1) . However, when the membrane was probed with either anti-caspase 6 or anti-PARP antibodies, it was evident that PDT-induced cleavage of these proteins was greatly reduced at a 25 µM concentration of Z-DEVD-fmk. The PDT-induced increase in hypodiploid DNA was also blocked at this concentration of the tetrapeptide inhibitor. A lower concentration of Z-DEVD-fmk (10 µM) did not block the cleavage of procaspase 6 or PARP, nor affect the appearance of hypodiploid levels of DNA (Figure 1 ). These results demonstrate that caspase 6 is activated by PDT and may occur downstream of caspase-3 processing.
Overexpression of Bcl-2 blocks caspase 3 and caspase 6 cleavage
To assess the influence of Bcl-2 overexpression and susceptibility to photodynamic killing, HL-60/neo or HL-60/Bcl-2 cells were incubated with or without BPD-MA and then exposed to light. Cells were lysed 1 h after light activation of BPD-MA. The status of Bcl-2, caspase 3 and caspase 6 in cytosolic extracts was Overexpression of Bcl-2 in HL-60 cells blocks the processing of procaspase 3 and procaspase 6 induced by treatment with BPD-MA and light. Cells were lysed 1 h after photosensitization. Cell lysates were separated by SDS-PAGE followed by Western immunoblotting. Cells were treated with light alone (2 J cm -2 ) (control), BPD-MA alone (100 ng ml -1 ) and light (PDT-100), or BPD-MA (200 ng ml -1 and light determined by Western immunoblotting. The control Bcl-2-transfected cells exhibited the expected greater band density of Bcl-2 (Figure 2 ). The electrophoretic status of Bcl-2 was unaffected by PDT treatment of either cell type (HL-60/neo or HL-60/Bcl-2). For cells treated with BPD-MA and light, caspase 3 and caspase 6 cleavage was evident for HL-60/neo cell lysates, but not in the HL-60/Bcl-2 cell extracts (Figure 2 ). These results suggest that Bcl-2 may indirectly or directly influence caspase 3 and caspase 6 activation produced by PDT.
Overexpression of Bcl-2 blocks caspase 3-like protease activity
Cell lysates were assayed for their capacity to cleave a fluorescently labelled caspase 3 substrate (Ac-DEVD-AMC) (Figure 3 ). Lysates prepared from HL-60/neo cells treated with BPD-MA and light exhibited high Ac-DEVD-AMC cleavage activity, whereas lysates from HL-60/Bcl-2 cells treated with the same levels of BPD-MA and light exhibited baseline levels of substrate cleavage. These results further support the observation that overexpression of Bcl-2 blocks activation of caspase 3 instigated by BPD-MA photoactivation. after PDT. Overexpression of Bcl-2 provided no observable protection at concentrations of BPD-MA at 50 or 100 ng ml -1 , as measured by MTT bioreduction over a 72-h period ( Figure 5 ). However, at lower concentrations of BPD-MA (10 or 25 ng ml -1 ), Bcl-2 overexpression did provide a degree of protection against photodynamic inactivation of a small proportion of cells which exhibited recovery over the 72-h test period.
Overexpression of Bcl-2 blocks PDT-induced increases in hypodiploid DNA
DISCUSSION
Overexpression of Bcl-2 has been shown to protect many different cancer cell lines from apoptosis induced by a wide variety of chemotherapeutic agents including dexamethasone, etoposide, methotrexate, cisplatin, cyclophosphamide, vincristine and 1-beta-D-arabinofuranosylcytosine (Ara-C) (reviewed in Reed, 1996) . It has been observed that Bcl-2 overexpression blocks caspase 3 activation and subsequent PARP cleavage in these systems (Ibrado et al, 1996; Estoppey et al, 1997; Perry et al, 1997) . In this study, we evaluated caspase activity, DNA fragmentation (as evidenced by an increase in hypodiploid DNA) and the viability of HL-60/neo or HL-60/Bcl-2 cells to determine whether treatment with cytotoxic levels of BPD-MA and light was regulated in a similar fashion in the setting of Bcl-2 overexpression. Overexpression of Bcl-2 prevented procaspase 3 and PARP cleavage produced by PDT. Such findings correspond to previous results obtained with these cells in which Ara-C was used as the apoptotic stimulus (Ibrado et al, 1996) . Procaspase 6 was also not processed in HL-60/Bcl-2 cells, indicating that Bcl-2 also acts upstream of caspase 6 activation in cells treated with BPD-MA and light. It has been demonstrated that caspase 6 may be responsible for degradation of nuclear lamins during apoptosis Neamati et al, 1995; Takahashi et al, 1996) . Lamin cleavage may be critical for the degradation of the nuclear envelope during apoptotic cell death . Studies by others have shown that caspase 3 can directly cleave procaspase 6 (Srinivasula et al, 1996) , suggesting that procaspase 6 cleavage does not occur in PDT-treated HL-60/Bcl-2 cells because of the absence of caspase 3 activity. Conversely, a recent report by Thornberry et al (1997) suggests that the optimal amino acid substrate sequence for caspase 6 resembles the activation site in effector caspase proenzymes such as caspase 3, suggesting that caspase 6 may act upstream of caspase 3 (Thornberry et al, 1997) . To determine whether caspase 6 activation occurred downstream of caspase 3, wild-type HL-60 cells were incubated with a caspase 3 inhibitor, Z-DEVD-fmk, before photoactivation of BPD-MA. The caspase 3 inhibitor did not block the appearance of the 12-kDa subunit of caspase 3, as produced by PDT, but did prevent the cleavage of procaspase 6 and PARP indicating that procaspase 6 cleavage is probably downstream of caspase 3 activation.
Cytosolic extracts prepared from HL-60/Bcl-2 cells exhibited minimal cleavage of the Ac-DEVD-AMC substrate in contrast to the HL-60/neo cells treated with the same amounts of BPD-MA and light. Interestingly, untreated HL-60/Bcl-2 cells, or those exposed to the photosensitizer in the absence of light, had a lower constitutive capacity to cleave the Ac-DEVD-AMC substrate than the HL-60/neo cells. This observation could be attributable to the presence of a minor proportion of apoptotic cells within the HL-60/neo cell population exhibiting caspase activity. Background levels of protease activity would be less for HL-60/Bcl-2 cells because overexpression of Bcl-2 inhibits caspase 3 activation (Ibrado et al, 1996) . Several studies have now demonstrated that cytochrome c may be necessary for the activation of caspase 3 and that Bcl-2 blocks the release of cytochrome c from mitochondria (Kluck et al, 1997; Yang et al, 1997) . Furthermore, it has recently been demonstrated that cytochrome c is involved in the activation of caspase 9, which is believed to then process caspase 3 (Li et al, 1997) . Whether this scenario transpires in PDT-treated cells will be examined in future studies.
For HL-60/Bcl-2 cells treated with BPD-MA and light, cell survival was not detected at photosensitizer concentrations of 50 ng ml -1 or greater at 72 h post PDT, suggesting that PDT may circumvent the inhibitory function of Bcl-2. The photodynamic treatment did not override the inhibitory effects of Bcl-2 with respect to caspase 3 and caspase 6 activation because procaspase 3 and 6 cleavage or DNA fragmentation did not occur in the HL-60/Bcl-2 cells that were treated with BPD-MA (100 ng ml -1 ) and light. This would suggest that a parallel biochemical pathway unrelated to caspases may be triggered in cells treated with higher levels of BPD-MA and light. At BPD-MA concentrations of less than 50 ng ml -1 , a modest protective effect of Bcl-2 overexpression against PDT-mediated cell death was observed in line with observations for other chemotherapeutic treatments . Although it has been well established by electron microscopy, histological and biochemical analysis that PDT induces apoptosis, we cannot rule out the possibility that PDT inflicts damage to other cell sites promoting passive necrotic cell death at higher drug concentrations (Gomer et al, 1988; Zaidi et al, 1993; Tajiri et al, 1996; Granville et al, 1997) . Further understanding towards the mechanisms involved in PDTinduced cell death and how this treatment may be able to overcome the regulatory control of Bcl-2 should provide valuable insights towards the improvement of current cancer treatments.
ABBREVIATIONS
Ac-DEVD-AMC, acetyl-Asp-Glu-Val-Asp-amino-4-methylcoumarin; BPD-MA, benzoporphyrin monoacid ring A, verteporfin, ICE, interleukin 1 converting enzyme; MTT, 3-(4,4-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide; PARP, poly(ADP-ribose) polymerase; PDT, photodynamic therapy; PI, propidium iodide; Z-DEVD-fmk, Z-Asp-Glu-Val-Asp-fluoromethylketone.
